Integrating deep learning and unbiased automated high-content screening to identify complex disease signatures in human fibroblasts
-
Published:2022-03-25
Issue:1
Volume:13
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Schiff Lauren, Migliori Bianca, Chen Ye, Carter Deidre, Bonilla Caitlyn, Hall JennaORCID, Fan Minjie, Tam Edmund, Ahadi Sara, Fischbacher BrodieORCID, Geraschenko Anton, Hunter Christopher J., Venugopalan SubhashiniORCID, DesMarteau Sean, Narayanaswamy Arunachalam, Jacob Selwyn, Armstrong ZanORCID, Ferrarotto Peter, Williams BrianORCID, Buckley-Herd Geoff, Hazard Jon, Goldberg Jordan, Coram MarcORCID, Otto Reid, Baltz Edward A., Andres-Martin Laura, Pritchard Orion, Duren-Lubanski Alyssa, Daigavane AmeyaORCID, Reggio Kathryn, Nelson Phillip C., Frumkin Michael, Solomon Susan L., Bauer Lauren, Aiyar Raeka S., Schwarzbach Elizabeth, Noggle Scott A., Monsma Frederick J., Paull DanielORCID, Berndl MarcORCID, Yang Samuel J.ORCID, Johannesson BjarkiORCID,
Abstract
AbstractDrug discovery for diseases such as Parkinson’s disease are impeded by the lack of screenable cellular phenotypes. We present an unbiased phenotypic profiling platform that combines automated cell culture, high-content imaging, Cell Painting, and deep learning. We applied this platform to primary fibroblasts from 91 Parkinson’s disease patients and matched healthy controls, creating the largest publicly available Cell Painting image dataset to date at 48 terabytes. We use fixed weights from a convolutional deep neural network trained on ImageNet to generate deep embeddings from each image and train machine learning models to detect morphological disease phenotypes. Our platform’s robustness and sensitivity allow the detection of individual-specific variation with high fidelity across batches and plate layouts. Lastly, our models confidently separate LRRK2 and sporadic Parkinson’s disease lines from healthy controls (receiver operating characteristic area under curve 0.79 (0.08 standard deviation)), supporting the capacity of this platform for complex disease modeling and drug screening applications.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference40 articles.
1. Chandrasekaran, S. N., Ceulemans, H., Boyd, J. D. & Carpenter, A. E. Image-based profiling for drug discovery: due for a machine-learning upgrade? Nat. Rev. Drug Discov. 20, 1–15 (2020). 2. Ando, D. M., McLean, C. & Berndl, M. Improving phenotypic measurements in high-content imaging screens. Preprint (2017). 3. Ashdown, G. W. et al. A machine learning approach to define antimalarial drug action from heterogeneous cell-based screens. Sci. Adv. 6, eaba9338 (2020). 4. Mohs, R. C. & Greig, N. H. Drug discovery and development: role of basic biological research. Alzheimers Dement. 3, 651–657 (2017). 5. Stokes, J. M. et al. A deep learning approach to antibiotic discovery. Cell 180, 688–702.e13 (2020).
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|